Source study found

Story checked

Targeted antibody therapy provides long-lasting relief from neuropathic pain (opens in a new tab)

news-medical.net · 2026-09-16

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

2 supported
6 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail

The story

Targeted antibody therapy provides long-lasting relief from neuropathic pain

news-medical.net · 2026-09-16

The story’s checkable claims.

Read the original story

NewsLink checks it

Mostly not supported

Every claim we could check holds up. Two of eight claims match the study. This overall rating is based only on the claims we could check. Six claims the study doesn't address.

2 supported
6 not covered

Open claim evidence

The source study

A Systemically Administered Humanized Anti-Nav1.7 Antibody with Long-Lasting Analgesic Activity and Preserved Physiological Nociception

Pharmaceutics · 2026

Open source record Open in Tessa

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

Reading mode

Scan verdicts. Open evidence only when needed.

Browse by verdict

8 claims in this story

Showing all 8 claimsChoose a verdict to focus the list.

Claim 1 of 8Not coveredIn cell tests, Clone1 and S-151128 selectively bound Nav1.7, reduced nerve-cell electrical activity, and showed at least 650-fold and 1300-fold selectivity, respectively, over other Nav subtypes tested.View evidenceHide evidence

As statedat least 650-fold and 1300-fold selectivity

Why this verdict

The abstract supports high-affinity, selective Nav1.7 binding and functional channel inhibition in cell-based assays. However, the supplied abstract-level profile does not provide the clone-specific names, numeric selectivity values of 650-fold and 1300-fold, assay details, or exact functional readouts needed to verify the full claim.

Study evidence

Humanized monoclonal antibodies showed high-affinity binding to Nav1.7 and were reported to be selective for Nav1.7 versus other voltage-gated sodium channel subtypes.

Claim 2 of 8Not coveredIn rats with partial sciatic nerve ligation, intravenously administered antibodies reduced sensitivity to mechanical stimulation in a dose-dependent manner, with effects at some doses comparable to pregabalin.View evidenceHide evidence

As statedcomparable to pregabalin at certain doses

Why this verdict

The abstract supports systemic antibody administration producing robust analgesia in PSNL rats, but it does not specify intravenous administration, dose-dependence, mechanical stimulation sensitivity details, or comparability to pregabalin at particular doses. Those details cannot be verified from the abstract-level profile.

Study evidence

Systemic administration of the lead humanized anti-Nav1.7 antibody produced robust analgesia in PSNL rats lasting at least 96 hours.

Claim 3 of 8Not coveredThe analgesic effects reportedly remained stronger than pregabalin 96 hours after treatment.View evidenceHide evidence

As stated96 hours after treatment

Why this verdict

The profile supports analgesia lasting at least 96 hours after systemic antibody administration. It does not report a pregabalin comparison at 96 hours, so the claim that effects remained stronger than pregabalin at that timepoint is not verifiable at abstract depth.

Study evidence

Systemic administration of the lead humanized anti-Nav1.7 antibody produced robust analgesia in PSNL rats lasting at least 96 hours.

Claim 4 of 8Not coveredThe antibody treatment reduced increased spontaneous activity and mechanical responses in spinal dorsal horn neurons and reduced mechanically induced pERK in dorsal root ganglion neurons.View evidenceHide evidence

Why this verdict

The abstract supports reduced mechanically evoked and spontaneous neuronal activity and reduced mechanical stimulus-induced pERK in DRG neurons after antibody treatment. However, the supplied profile explicitly lacks detail on the exact electrophysiological recording site, so the story’s specific reference to spinal dorsal horn neurons is not verifiable at this depth.

Study evidence

Systemic administration of the lead humanized anti-Nav1.7 antibody produced robust analgesia in PSNL rats lasting at least 96 hours.

Study evidence

Electrophysiological analyses demonstrated reduced mechanically evoked and spontaneous neuronal activity after systemic administration of the humanized anti-Nav1.7 antibody in PSNL rats.

Claim 5 of 8Not coveredIn animals without nerve injury, the antibodies did not significantly change responses to mechanical stimulation and did not significantly affect motor function, while pregabalin impaired performance at the tested dose.View evidenceHide evidence

Why this verdict

The abstract supports that the antibodies did not impair physiological nociception or motor function under tested conditions. It does not verify the more specific framing about animals without nerve injury, no significant change in mechanical responses, or pregabalin impairing motor performance at the tested dose.

Study evidence

Systemic administration of the lead humanized anti-Nav1.7 antibody produced robust analgesia in PSNL rats lasting at least 96 hours.

Claim 6 of 8Not coveredThe article says the findings are still preclinical and notes that the treatment was evaluated in only one neuropathic pain model, with antibody reach to the injured nerve not accurately measured.View evidenceHide evidence

Why this verdict

The abstract-level profile supports the preclinical nature of the findings and that evidence comes from a rat PSNL model. It does not report the limitation that antibody reach to the injured nerve was not accurately measured, so the full caveat statement cannot be verified at abstract depth.

Study evidence

Systemic administration of the lead humanized anti-Nav1.7 antibody produced robust analgesia in PSNL rats lasting at least 96 hours.

Claim 7 of 8SupportedResearchers targeted Nav1.7 with humanized antibodies to test whether they could provide long-lasting relief from neuropathic pain.View evidenceHide evidence

As statedlong-lasting relief

Why this verdict

The abstract-level profile supports that the researchers generated and humanized monoclonal antibodies targeting Nav1.7, tested their functional inhibition in cells, and evaluated systemic analgesic efficacy in a rat PSNL neuropathic pain model with effects lasting at least 96 hours. The story’s preclinical/hedged framing keeps the claim within the paper evidence.

Study evidence

Humanized monoclonal antibodies showed high-affinity binding to Nav1.7 and were reported to be selective for Nav1.7 versus other voltage-gated sodium channel subtypes.

Study evidence

Systemic administration of the lead humanized anti-Nav1.7 antibody produced robust analgesia in PSNL rats lasting at least 96 hours.

Claim 8 of 8SupportedThe story notes that S-151128 is currently in clinical trials.View evidenceHide evidence

Why this verdict

The supplied profile states that clinical advancement of S-151128 is noted, which supports the story’s statement that S-151128 is currently in clinical trials.

Study evidence

Systemic administration of the lead humanized anti-Nav1.7 antibody produced robust analgesia in PSNL rats lasting at least 96 hours.

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

Abstract lacks numerical effect sizes, sample sizes, dosing regimen, statistical details, and full assay methods
The story mentions major preclinical limitations and a model/antibody-distribution caveat, but it does not appear to discuss the abstract-level profile’s broader missing methodological and quantitative details. This is a depth/appraisal limitation rather than necessarily a flaw in the underlying article.
From in_vitro antibody generation and functional characterization; In vivo rat PSNL neuropathic pain model; systemic antibody

8 things the story did carry across

Development and humanization of monoclonal antibodies selectively targeting Nav1.7
In vitro selective binding to Nav1.7 and functional inhibition in cellular assays
Systemic administration in a rat partial sciatic nerve ligation neuropathic pain model produced robust, long-lasting analgesia lasting at least 96 hours
Evidence is preclinical and derived from a rat PSNL model, so human translatability is not established
Preservation of physiological nociception and motor function was reported only under tested preclinical assay conditions
Electrophysiological correlates: reduced mechanically evoked and spontaneous neuronal activity
Biomarker correlate: decreased mechanical stimulus-induced pERK in dorsal root ganglion neurons
S-151128 clinical advancement is noted

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalDemonstrate that systemic dosing of a lead humanized anti-Nav1.7 antibody produces robust, long-lasting analgesia in a rat neuropathic pain model while preserving physiological nociception and motor function.In vivo rat PSNL neuropathic pain model; systemic antibody administrationExpand

In plain English

In a rat partial sciatic nerve ligation (PSNL) neuropathic pain model, systemic administration of a lead humanized anti-Nav1.7 monoclonal antibody produced robust analgesia that lasted at least 96 hours. Electrophysiology showed reduced mechanically evoked and spontaneous neuronal activity, and immunohistochemistry demonstrated decreased mechanical stimulus–induced phosphorylation of ERK in dorsal root ganglion neurons. Under the tested conditions, the antibodies did not impair physiological nociception or motor function. These findings are presented as preclinical proof-of-concept for a long-acting, systemically delivered anti-Nav1.7 biologic analgesic.

Key findings

Systemic administration of the lead humanized anti-Nav1.7 antibody produced robust analgesia in PSNL rats lasting at least 96 hours.
Electrophysiological analyses demonstrated reduced mechanically evoked and spontaneous neuronal activity after antibody treatment.

What this piece can’t prove

Evidence is preclinical and derived from a rat PSNL model; translatability to humans is not established in this report.
Abstract does not provide numerical effect sizes, sample sizes, dosing regimen, or statistical analyses.

2 further details could not be confirmed from the summary.

2in vitroDevelop and humanize monoclonal antibodies that selectively bind Nav1.7 and inhibit Nav1.7 channel function in cellular systems.in vitro antibody generation and functional characterizationExpand

In plain English

The paper reports generation and humanization of monoclonal antibodies directed against Nav1.7 and in vitro characterization showing high-affinity, subtype-selective binding to Nav1.7 and functional inhibition of Nav1.7 channel activity in cell-based assays.

Key findings

Humanized monoclonal antibodies showed high-affinity binding to Nav1.7 and were reported to be selective for Nav1.7 versus other voltage-gated sodium channel subtypes.
Humanized antibodies functionally inhibited Nav1.7 channel activity in cellular assays.

What this piece can’t prove

The abstract does not specify the exact cell-based assay formats or controls used to demonstrate functional inhibition.

2 further details could not be confirmed from the summary.

3in vivo animalShow mechanistic/biomarker and neurophysiologic correlates of analgesia in vivo (reduced evoked/spontaneous neuronal activity; reduced stimulus-induced pERK in DRG neurons).In vivo electrophysiology and immunohistochemistry in PSNL ratsExpand

In plain English

In a rat partial sciatic nerve ligation (PSNL) model of neuropathic pain, systemic administration of a humanized anti-Nav1.7 monoclonal antibody was associated with reduced mechanically evoked and spontaneous neuronal activity measured by electrophysiology, and with decreased mechanical stimulus–induced phosphorylation of ERK in dorsal root ganglion neurons (immunohistochemistry). The abstract reports these neurophysiologic and biomarker changes alongside preserved physiological nociception and motor function.

Key findings

Electrophysiological analyses demonstrated reduced mechanically evoked and spontaneous neuronal activity after systemic administration of the humanized anti-Nav1.7 antibody in PSNL rats.
Immunohistochemistry showed decreased mechanical stimulus–induced phosphorylation of ERK (pERK) in dorsal root ganglion neurons after antibody treatment.

What this piece can’t prove

4 further details could not be confirmed from the summary.

4ex vivo animalShow mechanistic/biomarker and neurophysiologic correlates of analgesia in vivo (reduced evoked/spontaneous neuronal activity; reduced stimulus-induced pERK in DRG neurons).DRG immunohistochemistry for stimulus-induced pERK after systemic antibody treatment in PSNL ratsExpand

In plain English

In a rat partial sciatic nerve ligation (PSNL) neuropathic pain model, systemic administration of a humanized anti-Nav1.7 antibody was associated with reduced mechanical stimulus–induced phosphorylation of extracellular signal-regulated kinase (pERK) in dorsal root ganglion (DRG) neurons measured by immunohistochemistry (reported in the paper abstract). Quantitative details and assay parameters are not provided in the abstract.

Key findings

Systemic administration of the lead humanized anti-Nav1.7 antibody was reported to reduce mechanically evoked phosphorylation of ERK (pERK) in DRG neurons from PSNL rats, as measured by immunohistochemistry.

What this piece can’t prove

3 further details could not be confirmed from the summary.

Finally, the search trail

Method layer